博騰股份（股票代碼：300363）成立于2005年，是國內(nèi)領(lǐng)先的醫(yī)藥合同定制研發(fā)及生產(chǎn)企業(yè)（CDMO），我們?yōu)槿蛩幤?、新藥研發(fā)機構(gòu)等提供從臨床早期研究直至藥品上市全生命周期所需的化學(xué)原料藥、化學(xué)制劑和生物藥的定制研發(fā)和生產(chǎn)服務(wù)。作為一家國家高新技術(shù)企業(yè)，博騰為全球知名藥企及藥物研發(fā)機構(gòu)長期提供卓越的端到端CDMO服務(wù)，我們的研發(fā)、生產(chǎn)和運營機構(gòu)遍及中國、美國、比利時、瑞士和英國。
博騰致力于成為全球最開放、最創(chuàng)新、最可靠的制藥服務(wù)平臺，讓好藥更早惠及大眾。我們擁有領(lǐng)先的研發(fā)技術(shù)平臺能力、完善的質(zhì)量管理體系、EHS管理體系和良好的交付記錄，生產(chǎn)基地先后通過NMPA、FDA、PMDA、EMA和WHO權(quán)威認(rèn)證。我們開放近十余年服務(wù)全球知名藥企的經(jīng)驗和國際一流CDMO平臺來積極支持國內(nèi)藥企的發(fā)展，加速新藥上市進程，全面為國內(nèi)化學(xué)和生物制藥、藥物研發(fā)機構(gòu)等提供創(chuàng)新藥CMC服務(wù)、MAH委托生產(chǎn)服務(wù)、臨床試驗服務(wù)、創(chuàng)新藥中間體、原料藥到制劑的定制研發(fā)及生產(chǎn)服務(wù)和生物基因與細(xì)胞CDMO服務(wù)。
?
With over 3,000 customer-centric employees, operations and commercial offices across the US, EU and China, Porton Pharma Solutions provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and manufacturing services across small molecule APIs, dosage forms and biologics.
Our Process Technology Centers and USFDA/EMA/PDMA/NMPA/WHO-inspected Manufacturing Facilities feature state-of-the-art equipment, highly flexible cGMP-compliant production assets, plus over 500 highly skilled scientists and process engineers, all backed by a proven program management system dedicated to seamlessly delivering successful outcomes for your unique project requirements.
We are committed to be the most open, innovative and reliable pharmaceutical service platform in the world and Enabling public’s early access to good medicines. We constantly strive for excellence, and have been recognized through awards by industry forums and global pharmaceutical companies for our process innovation, supply chain performance and compliance with global Quality and EHS standards. By efficiently advancing development and enabling commercialization of multiple high-impact medicines, Porton is proud to have earned the trust of some of the world’s leading and most innovative pharmaceutical companies and many biotechnology companies across the US, EU and Asia.
?
?